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Abstract
This report summarizes the presentations and discussion in the first Japan Clinical Oncology
Group-European Organisation for Research and Treatment of Cancer Quality of Life/Patient-
Reported Outcome workshop funded by the National Cancer Center Hospital that was held on
Saturday, 1 September 2018 in Tokyo, Japan. The infrastructure and understanding regarding the
Quality of Life/Patient-Reported Outcome assessment of cancer patients in Japan is still immature,
in spite of the increased demand for oncological Patient-Reported Outcome research felt not
only by researchers but also by patients or other stakeholders of cancer drug development.
The workshop aimed to share each perspective, common issues to be considered and future
perspectives regarding the strong alliance between the European Organisation for Research and
Treatment of Cancer Quality of Life Group and the Japan Clinical Oncology Group for Quality
of Life/Patient-Reported Outcome research as well as explore the possibility of conducting col-
laborative research. European Organisation for Research and Treatment of Cancer is a leading
international cancer clinical trials organization, and its Quality of Life Group is a global leader
in the implementation of Quality of Life research in cancer patients. The three invited speakers
from the European Organisation for Research and Treatment of Cancer Quality of Life Group
presented their perspective, latest methodology and ongoing projects. The three speakers from
the Japan Clinical Oncology Group presented their current status, experience and some issues
regarding data management or interpretation of the Patient-Reported Outcome data. The two
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2 The JCOG-EORTC QOL/PRO workshop in Japan
patient advocates also shared their expectations in terms of advances in cancer research based on
the Patient-Reported Outcome assessment. As the next steps after this workshop, the Japan Clinical
Oncology Group and European Organisation for Research and Treatment of Cancer have decided
to cooperate more closely to facilitate Patient-Reported Outcome research in both the groups, and
the Japan Clinical Oncology Group has approved the establishment of a new committee for Quality
of Life/Patient-Reported Outcome research in Japan.
Key words: quality of life, patient-reported outcome measures, international cooperation, surveys and questionnaires
Overview
Global developments in novel cancer treatments have progressed
rapidly. Objective endpoints, such as overall survival and rate of
adverse events, have been used for evaluating the efficacy and safety
of new treatments in cancer clinical trials, supporting the practice
of evidence-based medicine. In contrast, the concept that the experi-
ences and opinions of cancer patients undergoing treatment should
be better reflected in the process of treatment development (patient-
centered medicine) is prevalent in Western countries. In 2009, the
Food and Drug Administration (FDA) published guidelines on the
use of patient-reported outcome (PRO) measures in medical product
development (1), and the European Medicines Agency has developed
guidelines for the use of PRO measures in oncology studies (2).
However, the infrastructure for the assessment and interpretation
of PRO data in cancer trials in Japan is underdeveloped and is
still immature. The Japan Clinical Oncology Group (JCOG) is the
leading multicenter clinical study group in Japan that has conducted
nationwide clinical trials to establish effective standard treatments
for various types of malignant tumors. However, the JCOG has
maintained a cautious approach toward the implementation of qual-
ity of life (QOL) assessment of cancer patients in their trials with
concerns about the subjectivity of the QOL data, the complexity of
the interpretation as well as the patient and administrative burden
for QOL data collection.
The European Organisation for Research and Treatment of
Cancer (EORTC) is an independent, nonprofit international cancer
research organization that coordinates and conducts clinical trials
for improving the standard of care for cancer patients. In 1980, the
EORTC Quality of Life Group (EORTC QLG) was created to advise
the EORTC headquarters and the various cooperative groups on the
design, implementation and analysis of QOL studies within selected
phase III clinical trials.At the time of writing this report, there are 397
QOL researchers who are members of the EORTC QLG and attend
the meetings regularly, according to the QLG newsletter (3) provided
by the current secretary of the EORTC QLG, Karin Kuljanic. The
EORTCQLG has developed and refined questionnaires for assessing
health-related QOL (HRQL) for use in oncology clinical trials (e.g.
EORTC QLQ-C30), and these well-validated questionnaires have
been globally used in clinical trials and clinical practice. From 2003
to 2017, 53 EORTC trials included QOL assessment (Tables 1a and
1b), and there are ongoing projects that aim to understand the effects
of cancer and its treatment on the QOL of diverse populations of
cancer patients across different cultures.
Recently, the JCOG and the EORTC strengthened their ties
to facilitate intercontinental collaborations through conducting
collaborative trials and projects (e.g. EORTC-1527-GITCG-
IG: DREAM—Diffusion-Weighted Magnetic Resonance Imaging
Assessment of Liver Metastasis to Improve Surgical Planning, and
the first JCOG-EORTC scientific symposium took place in December
2017 in Tokyo) (4,5). For further cooperation, the gap in the
stance about QOL research between EORTC and JCOG should be
bridged.
The JCOG has organized this first-ever workshop on QOL/PRO
research for cancer in collaboration with the EORTC. The workshop
aimed to share the approaches and policies on QOL research of
both organizations, discuss current global issues and focus on future
perspective on collaborative QOL projects across the EORTC and
the JCOG.
Part 1: the EORTC Quality of Life Group’s
perspective
Quality assurance of QOL: how to develop ways to
ensure robustness in QOL assessment and tools as
well as in the creation of policies and standards of
practice in instrument validation
FM (Specialist in Quality of Life, EORTC, Brussels, Belgium) first
presented an overview on the history ofQOL research and terminolo-
gy/concept, highlighting the difference between the HRQL and PRO.
HRQL is a multi-domain concept that represents the patient’s general
perception of the effect of illness and treatment on the physical,
psychological and social aspects of life. PRO is a measurement based
on a report that comes directly from the patient about the status
of his/her health condition without amendment or interpretation of
the patient’s response by a clinician or anyone else. Thereafter, she
discussed the procedure to develop a questionnaire or a module for
HRQL assessment according to the EORTC Quality of Life Group
(QLG) guidelines (6) with some examples. The term ‘questionnaire’ is
used in reference to a stand-alone instrument,while the term ‘module’
refers to an instrument that needs to be administered in conjunction
with a questionnaire.
The QLG started working on the development of the first ques-
tionnaire to measure the QOL in cancer patients as a self-reported
outcome in 1980. The result of this work was the creation of a core
questionnaire, the QLQ-C30 (7), that has been translated into over
110 languages and has been used, in the current version, since 1993.
Other instruments have been developed thereafter; these are
not disease-specific, and organizations other than the QLG have
developed them. Research organizations worldwide have developed
tools to assess the specific aspects of the QOL in different subgroups
of cancer patients.
FM showed the practical steps to develop a well-designed ques-
tionnaire or a module as per the QLG guidelines (8), including
the several phases (phase 1–4), starting from conception to the
development and validation of the desired instrument. This part of
the talk focused on the conceptual work and the practical details,
with examples and hints regarding the importance of cross-cultural
validation as well as static (non-customizable) and dynamic (cus-
tomizable) questionnaires (9).
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Table 1a. Number of EORTC trials as per the publication year (2003–2017)
Year CTs with NO QOL CTs with QOL TOTAL % CTs with QOL
2003 14 3 17 18%
2004 17 2 19 11%
2005 6 2 8 25%
2006 10 3 13 23%
2007 9 2 11 18%
2008 5 4 9 44%
2009 5 3 8 38%
2010 4 2 6 33%
2011 2 6 8 75%
2012 6 1 7 14%
2013 6 5 11 45%
2014 9 2 11 18%
2015 12 6 18 33%
2016 8 4 12 33%
2017 8 8 16 50%
Total 121 53 174 30%
EORTC, European Organisation for Research and Treatment of Cancer; CTs, clinical trials; QOL, quality of life.
Table 1b. Number of trials as per the EORTC Group (2003–2017)
EORTC group CTs with NO QOL CTs with QOL Total % CTs with QOL
BTG 10 11 21 52%
STBSG 13 6 19 32%
ROG 3 3 6 50%
LCG 15 3 18 17%
GITCG 15 4 19 21%
Melanoma group 4 2 6 33%
GUCG 5 5 10 50%
BCG 12 9 21 43%
GCG 3 4 7 57%
HNCG 5 1 6 17%
Leukemia group 6 1 7 14%
CLG 2 2 4 50%
Elderly task force 1 1 2 50%
Other groups 28 0 28 0%
Total 121 53 174 30%
BTG, brain tumor group; STBSG, soft tissue and bone sarcoma group; ROG, radiation oncology group; LCG, lung cancer group; GITCG, gastrointestinal tract
cancer group; GUCG: genito-urinary cancer group; BCG, breast cancer group; GCG, gynecological cancer group; HNCG, head and neck cancer group; CLG,
children’s leukemia group.
FM also provided guidance on a common question: ‘How to
choose a good tool?’. Given the multidimensional nature of QOL,
the measurement requires a valid and reliable instrument that is able
to assess the target parameters accurately and to provide an answer to
the research question. Preference should always be given to validated
instruments.
Once the tool is chosen and data are collected, it is time for the
analyses. While talking about the analyses techniques, FM pointed
out the importance of the interpretation of PRO/HRQL data. While
analyzing the QOL data, researchers should consider not only the
statistical significance but also the clinical interpretation. In other
words: ‘A difference is a difference when it makes a difference’.
Without clinical significance, a number is just a number; however,
with the correct interpretation, the same number can become an
important source of clinically relevant information.
Design and analysis of PROs and HRQL endpoints in
randomized controlled trials on cancer patients
MP (Specialist in QOL, EORTC, Brussels, Belgium) presented on the
current trends regarding the increase in the number of trials that
have assessed PRO and HRQL data; further, many stakeholders are
interested in the assessment of PROs that can be used to integrate
patient perspective into the drug development process. However,MP
also mentioned the lack of set standards on how to analyze PRO data
statistically, a factor that could hamper the interpretation of PRO
findings.
An example was provided. Two trials with the same population,
trial design, and treatment arms showed discrepant conclusions
regarding HRQL outcomes (10,11). The discrepancy could mislead
people to regard PRO and HRQOL assessment in cancer trials as
not being useful. However, in the light of PRO research, the different
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design and statistical analysis decisions could lead to different results.
MP presented the importance of standardizing the statistical analyses
of PRO and HRQL data to resolve the inherent issues of PRO data
that are mentioned above. She has been in charge of the Setting Inter-
national Standards in Analyzing Patient-Reported Outcomes and
Quality of Life Endpoints Data for Cancer Clinical Trials (SISAQOL)
project (12) that aims to provide recommendations on the methods
of standardizing the analysis of HRQL and other PRO data in
cancer randomized trials. She stressed that more specific hypothesis,
research questions, and objectives are needed and that ‘to evaluate if
QOL is improved’ is insufficient as a research objective. Finally, she
presented how to classify and handle missing data (13). Statistical
methods that can handle the missing data were also presented. Issues
in the use of statistical methods were discussed, with a focus on
demonstrating the importance of identifying the reasons for missing
PRO assessments. Finally, missing data is almost inevitable in cancer
randomised controlled trials (RCTs); therefore, the importance of
sensitivity analysis to test the different assumptions about missing
data was emphasized to ensure the robustness of the PRO findings.
More information about the recommendations from the SISAQOL
initiative has recently been published (14).
The role of PRO and QOL measures in trials and
clinical practice
GV (Professor of Medical Oncology, University of Leeds and Leeds
Cancer Centre, Leeds, United Kingdom) first presented on the role of
PRO/HRQL assessment in cancer clinical trials. Conventional clinical
methods can be supplemented by PRO measures. The potential role
of PROs is recognized and endorsed by national and international
practice guidelines. For example, the UK TACT2 trial (15) was a
phase III randomized controlled trial with 2 × 2 factorial design
that aimed to test two hypotheses for breast cancer: whether the
use of accelerated epirubicin was able to improve overall survival
as compared to standard epirubicin and whether the use of oral
capecitabine instead of standard combination chemotherapy (CMF)
would be comparable in terms of overall survival, cause less tox-
icity and improve the QOL. The conclusion was that accelerated
epirubicin did not offer greater efficacy; however, the PRO data
showed worse symptoms, functioning and HRQOL scores with
accelerated epirubicin than with standard epirubicin. Therefore,
accelerated epirubicin could not be recommended as an alternative
to epirubicin for moderate–risk, early-breast cancer patients. For the
second hypothesis, capecitabine was as efficacious as CMF when
following anthracycline chemotherapy; however, patients assigned to
the CMF arm reported significantly more serious adverse effects that
influenced their functioning and HRQL, with differences persisting
for 12 and 24 months after the treatment. Based on both the overall
survival and HRQOL results, the TACT2 trial recommends against
the use of accelerated epirubicin for moderate–risk, early-breast
cancer and confirms that oral capecitabine is as efficient but less toxic
than standard CMF. Thus, the HRQOL data provided important
information for clinicians and patients to support their treatment
decisions.
Second, GV presented novel PRO concepts for cancer clinical
trials. Conventionally, the tolerability of cancer treatment has been
assessed mainly based on the clinician’s safety data (e.g. CTCAE or
other adverse events); however, several studies showed discrepancies
between the adverse events or symptoms reported by clinicians and
patients. The use of PRO data could be potentially beneficial to
stakeholders engaged in drug development (Table 2). Regulatory
Table 2. Potential beneficiaries of patient-reported adverse symp-
toms in cancer treatment trials
Stakeholder Potential benefits
Clinical trial
participants
Earlier detection of toxic effects
through improved communication
with clinical staff
Investigators
and/or sponsors
More complete adverse event data
during drug development
Regulatory
agency reviewers
Additional toxicity data to balance
safety with efficacy during regulatory
review
Clinicians Improved information about prior
patients’ experiences with treatments,
for use when counseling future patients
or assessing adverse reactions
Future patients Access to information about prior
patients’ experiences with particular
treatments, to inform therapy decisions
agencies, such as the FDA, recommend the use of well-validated
and reliable PRO measurements, such as the NCI PRO-CTCAE
(16) and the EORTC item libraries (17), to complement existing
clinical safety assessments and assess cancer treatment tolerability.
Some investigators may not be confident about implementing PRO
assessment in clinical trials, and some studies are ongoing to check
the feasibility of collecting PRO data in multicenter cancer clinical
trials (18).
The third part of her presentation focused on the use of PROs
in clinical practice to monitor symptoms and adverse effects during
cancer treatment. There is increasing research evidence showing that
the use of PROs in individual patient care in oncology is beneficial to
patients, supports communication, achieves better symptom control
and results in higher survival rates (19–21). A brief overview of this
evidence was provided, followed by an example of her experience, in
Leeds, UK, of online monitoring of toxicity during cancer chemother-
apy using data on patient-reported adverse effects integrated with
the electronic patient records (electronic patient self-reporting of
adverse events: Patient Information and aDvice—electronic patient
self-Reporting of Adverse-events: Patient Information and aDvice
(eRAPID) research program funded by the National Institute for
Health Research) (Fig. 1) (22,23). The values and challenges involved
in integrating PRO data into routine oncology practice were also
presented.
Part 2: current status of PRO and QOL
assessment in Japan
Summary of QOL/PRO in the JCOG studies
JM (Coordinating Statistician, JCOG Data Center, Tokyo, Japan)
presented the timeline of QOL/PRO research in the JCOG and the
current issues to be solved for further implementation of HRQL
assessment in clinical trials.
The timeline was split into the following two time frames: (i)
1990–2004 and (ii) 2005–2017.
1990–2004: before the establishment of the JCOG QOL policy. In this
period, 19 of the 44 randomized phase III trials and 5 of the 72
nonrandomized and/or phase I and II trials includedQOL assessment
as their endpoints (Table 3a). The proportion of completed QOL
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Figure 1. eRAPID systemic RCT diagram.
assessments in the trials of each tumor type was 37.5% (3/8) in lung
cancer, 75% (3/4) in gastrointestinal cancer, 0% (0/3) in lymphoma,
100% (2/2) in urological cancer and 14.2% (1/7) in breast cancer.
Overall, the QOL assessment was completed in only 37.5% (9/24)
of all JCOG trials with QOL assessment. Some of the questionnaires
or modules used in these trials were ad hoc questionnaires, and no
person was in charge of data management for the collected QOL data
in 15 out of the 24 trials.
Given the situation, the JCOG QOL unit was founded in 1997
to establish a feasible and valuable QOL assessment method in
the JCOG with limited budget and human resources. Consecutively,
the QOL unit conducted a feasibility study JCOG9803 aiming to
evaluate the feasibility of QOL assessment and establish a method
to manage QOL assessment, including data management. All the
patients enrolled in the JCOG9802 (a randomized phase III trial
to compare doxorubicin plus cyclophosphamide (AC), single-agent
docetaxel (D) and an alternating regimen of AC and D (AC-D)
as first-line chemotherapy in metastatic breast cancer) (24) were
consulted and registered in an additional QOL study JCOG9803.
The questionnaires used were the Functional Assessment of Cancer
Therapy (FACT)-Breast cancer (25) and FACT-Taxane (26), and time
points of assessment were baseline, 6 weeks after treatment initiation
and 18 weeks after treatment initiation. Data were managed and
reminders were sent by the JCOG QOL unit, and total 150 patients
were enrolled. The data collection rates were 99, 89 and 87% at
baseline, 6 and 18 weeks, respectively. Although the data collection
rate was favorable, the practical administrative burden on the JCOG
QOL unit for collecting the data rigorously was larger than expected;
thus, it was concluded that it was not feasible for the JCOG Data
Center and the QOL unit to support QOL data management of all
the JCOG trials, considering the limited resources.
In 2003, the JCOG QOL ad hoc committee was established to
develop a policy regarding QOL assessment in the JCOG trials. The
committee members discussed the experience and reached the fol-
lowing consensus recommendations: validated questionnaires with
a patient self-reporting format should be used, and at least one
investigator from each study group should be appointed as the QOL
study coordinator. This policy is available at the following link:
http://www.jcog.jp/basic/policy/index.html.
2005–2017: after the establishment of the JCOG QOL policy. In this
latter time frame, 8 of the 62 randomized phase III trials and 1
of the 43 nonrandomized and/or phase I and II trials included
QOL assessment as their endpoint (Table 3b); further, the pro-
portion of JCOG trials with QOL assessment has reduced from
20.7% (24/116; 1990–2004) to 8.1% (9/111; 2005–2017).However,
QOL assessment has been completed in all the trials with patient
accrual completion (5/9) according to the QOL policy. Although
the proportion of trials with QOL assessment has decreased, the
completion of QOL assessment has improved because of the efforts
of the exclusive QOL coordinator who was in charge of data
management.
For higher use of QOL assessment in JCOG trials, some issues
need to be resolved at both the JCOG Data Center and local sites.
Considering the limited resources at the JCOG Data Center, it is
not feasible for the center to manage all data collection activities. In
addition, the infrastructure for clinical trials at local sites could still
be under developed for QOL assessment, while the support from the
clinical research coordinator has improved.
The reason for unwillingness to use QOL assessment
for clinical trials
HF (Director, JCOG Date Center, Tokyo, Japan) presented some
inherent issues regarding the consideration of PRO/HRQL data in
open-label clinical trials. First, he argued that the value of collecting
D
ow
nloaded from
 https://academ
ic.oup.com
/jjco/advance-article/doi/10.1093/jjco/hyaa119/5890826 by N
ational C
ancer C
enter Library user on 12 August 2020
6 The JCOG-EORTC QOL/PRO workshop in Japan
Table 3a. Number of JCOG trials with or without QOL assessment (1990–2004)
Groups Randomized phase III trials Nonrandomized and/or phase I/II Total % CTs having
QOL
With NO QOL With QOL With NO QOL With QOL
LCSG 4 7 26 1 38 21%
LCSSG 3 0 6 0 9 0%
GICG 2 1 8 0 11 9%
GCSSG 4 2 4 0 10 20%
JEOG 3 0 3 0 6 0%
CCSG 2 1 0 0 3 33%
BCSG 2 4 3 3 12 58%
LSG 3 2 13 1 19 16%
GyCSG 1 0 2 0 3 0%
UOSG 0 2 0 0 2 100%
BSTTSG 0 0 1 0 1 0%
RTSG 0 0 1 0 1 0%
BTSG 1 0 0 0 1 0%
Total 25 19 67 5 116 21%
LCSG, lung cancer study group; LCSSG, lung cancer surgical study group; GICG, gastrointestinal cancer group; GCSSG, gastric cancer surgical study group;
JEOG, Japan esophageal oncology group; CCSG, colorectal cancer study group; BCSG, breast cancer study group; LSG, lymphoma study group; GyCSG,
gynecologic cancer study group; UOSG, urologic oncology study group; BSTTSG, bone and soft tissue tumor study group; RTSG, radiation therapy study group;
BTSG, brain tumor study group.
Table 3b. Number of JCOG trials with or without QOL assessment (2005–2017)
Groups Randomized phase III trials Nonrandomized and/or phase I/II Total % CTs with QOL
With NO QOL With QOL With NO QOL With QOL
LCSG 3 4 2 0 9 44%
LCSSG 6 0 2 0 8 0%
GCSG 8 2 5 0 15 13%
JEOG 4 1 3 0 8 13%
CCSG 8 1 2 0 11 9%
HBPOG 4 0 4 0 8 0%
GIESG 2 0 5 0 7 0%
BCSG 3 0 1 0 4 0%
LSG 3 0 5 0 8 0%
GyCSG 3 0 3 0 6 0%
UOSG 2 0 0 0 2 0%
BSTTSG 3 0 0 0 3 0%
RTSG 2 0 5 1 8 13%
BTSG 6 0 1 0 7 0%
HNCSG 2 0 2 0 4 0%
DOG 1 0 2 0 3 0%
Total 60 8 42 1 111 8%
GCSG, gastric cancer study group; HBPOG, hepatobiliary and pancreatic oncology group; GIESG, gastrointestinal endoscopy study group; HNCSG, head and
neck cancer study group; DOG, dermatologic oncology group.
QOL data in clinical trials for decision-making of cancer treatment
remained uncertain. He mentioned the following reasons:
(a) Clinical meaning: difference or improvement in the QOL
scores cannot be translated into clinical significance. ‘Reducing
%Grade3-4 diarrhea by 10%’ is understandable by the
patients as well as physicians; however, the clinical meaning
of ‘reducing QOL score by 10%’ is not understandable by
everyone.
(b) Usefulness in the choice of better treatment: in the noninferiority
trial, survival was non-inferior in the NEW therapy group,
toxicity was equivalent, and the QOL score was better in the
NEW group; thus, NEW was chosen as the new standard
therapy. In the superiority trial, survival did not differ,NEWwas
more toxic, and the QOL score was better in the NEW group;
however, NEW was not chosen. Therefore, the QOL results in
superiority trials do not affect the treatment choice.
Second, HF presented concerns about the validity of the QOL
data:
(a) Information bias: cancer treatment trials are rarely masked
(formerly called ‘blinded’) for assigned treatment, except
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supportive treatment trials (e.g. antiemetic drug) because
notification of the expected toxicity to the patients is essen-
tial to minimize patient risk during treatment. However,
notification of toxicity information inevitably causes infor-
mation bias in the patient’s responses to the questionnaires
(e.g. patients receiving cisplatin are likely to give a low [bad]
score for gastrointestinal toxicity questions). This bias is
never eliminated in open-label trials and is rarely mentioned
as a limitation in trials on HRQOL and PROs.
(b) Missing data/informative censoring: missing data is a com-
mon source of bias in HRQOL. No solution has been
established despite the proposal of many methods.
(c) Physician’s underestimation of the severity of symptoms:
similar underestimation that may have occurred in the
treatment arms may not cause significant biases in treat-
ment evaluation.
Finally,HF expressed apprehension regarding the respondent bur-
den of patients. The HRQOL questionnaire is not a burden-free inter-
vention. It requires not only time but also may cause mental burden
for the patients, such as increased risk of depression.Mills et al. found
that lung cancer patients who completed regular QOL questionnaires
that were not reviewed by their physicians reported worse QOL (27).
HF concluded that most of the above problems cannot be resolved
and HRQOL/PRO would only be useful in double-masked sup-
portive treatment trials in the field of oncology. In double-masked
crossover randomized trials, the following simple question should be
asked to the patient, ‘Which do you prefer, the former drug or the lat-
ter?’. If significantly more patients choose drug A over drug B,we can
confidently conclude that drug A is the better drug. HRQOL/PRO
could provide a very complicated answer to a simple question.
Experience of involvement in the EORTC QLG and
module development
KN (MD, PhD, Kobe University Hospital Cancer Center, Hyogo,
Japan) is a medical oncologist of head and neck cancer (HNC).
He presented some unique QOL issues of patients with HNC who
were treated with surgery, chemotherapy and radiation therapy; such
alterations in the QOL due to disease and treatment could not be
captured via conventional assessment of adverse events or symptoms.
Thus, KN started to implement some modules (e.g. the EORTC
QLQ-HN35) for assessing the HRQL in HNC patients. However,
he has realized that it is not enough to only use a module devel-
oped in another region and translated the module into Japanese, in
consideration of the cultural and, possibly, psychosocial differences
betweenWestern countries and Japan. In order to reflect the Japanese
perspective in module development, he has been involved in the HNC
module update and development projects (EORTC QLQ-HN43,
QLQ-THY34) (28–31) and has been attending the EORTC QLG
meeting since 2013, being the first active Japanese member of the
QLG since 2015. He stressed that for further progress of HRQL and
PRO research in Japan, a more organized collaboration between the
EORTC and JCOG is crucial so that the role of HRQL assessment
in cancer patients is increasingly recognized and implemented by
Japanese researchers, physicians and patients.
Part 3: QOL from the perspective of the cancer
patient
LG (President, Japan Brain Tumor Alliance) and YM (President,
PanCAN Japan) presented the value of PRO in clinical trials and
practice based on their experiences as patients. LG mentioned her
experience first and then discussed the importance of tracking PRO
data. With respect to clinical care, given the discrepancy between the
reports by the physicians and patients (32,33), the use of clinical
reports from both the physicians and patients is crucial for proper
treatment decision and symptom control. For the administration of
new drugs, such as molecularly targeted therapy and immunotherapy,
PRO data could be useful to assess and manage the unique symp-
toms of each patient because these new drugs exert diverse adverse
effects.
YM stressed on the importance of PRO, considering the cost and
benefit balance of treatment, that is, the treatment value. Recently,
there has been a shift toward enhancing evidenced-based medicine
with value-based medicine (VBM). VBM is more than just managing
the drug costs and forms a part of the broader debate on access to
treatment that includes different stakeholder expectations regarding
value in cancer care. Another shift has been observed from a product-
oriented approach, rooted in science and efficacy, to a broader
assessment that includes pharmacy economics, therapy management,
compliance issues and QOL. Considering these global trends, the
role of patient advocacy groups among stakeholders will become
more important, and the PRO data will help in understanding patient
experiences in cancer care and using patient perspectives for drug
development.
Panel discussion
First, MT (Medical research fellow, EORTC, Brussels, Belgium) was
asked how we should consider the information bias in the QOL/PRO
researches. MP responded that the information bias could affect not
only the PRO data but also other conventional trial endpoints, such
as adverse events according to CTCAE, as assessed by investigators
who are aware of the hypothesis; the information bias in open-label
trials should be considered; however, this is not a unique issue of PRO
assessment. GV commented, based on her oncology practice, that
patients are exposed to a lot of information about efficacy, possible
complications, adverse effects of treatment as well as the details of the
clinical trial. It is often hard for them to retain all this information,
and therefore unlikely the knowledge of potential side effects will
cause the patients actually experiencing them.
Second, MT asked whether it was feasible to prioritize the
assessment of disease symptoms, physical function and symptomatic
adverse events over emotional well-being, social well-being and
cognitive function, as suggested by the FDA (34). FM responded that
the assessment of physical function or adverse events was crucial,
considering that they would be affected directly by cancer treatment.
However, each domain in a questionnaire is deeply interconnected;
therefore, focusing on the assessment of a specific domain could
allow missing out on important information about the impact of
QOL. GV added that we should consider the type of cancer while
assessing the QOL of the patients. For instance, the assessment
of social functioning in addition to physical functioning of HNC
patients would be useful to measure their HRQL. The domains to
be prioritized or assessed should depend on the types of cancer,
treatment and trial design.
Given the limited resources for cancer trials in Japan, it is imprac-
tical to collect complete QOL data for all domains using a ques-
tionnaire or a module. If the QOL endpoint in a trial is the change
in the physical functioning score from that at baseline to that after
12 months of treatment, we should only collect data on physical
functioning because collecting data about other domains would be
less meaningful and add to the investigator burden. However, MP
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argued that collecting the whole QOL data would be useful for
forming a new hypothesis and would be informative for patients
with similar disease evaluated in the trials and investigators who
were interested in the treatment strategy of the cancer. It would
be regrettable if the chance to collect crucial data on QOL in one
trial is lost because the cost of conducting clinical research has been
increasing. Collecting as much data as possible in one trial would be
more efficient from the long-term standpoint.
The final topic was how we could encourage and reinforce
a collaboration between the EORTC QLG and JCOG. YM first
mentioned that from the patient perspective, they hoped more cancer
patients would participate in clinical trials. The international collab-
oration could be one of the ways to increase the number of trials for
which patients are eligible and facilitate the use of PRO assessment
in Japan. For more efficiency and less burden on the patients and
investigators, an electronic platform to collect PRO data should be
developed. GV and KN (Director, JCOG Operation Office, Tokyo,
Japan) proposed a joint development project of an electronic record
system as a future collaboration.
Sustainable long-term cooperation would be crucial for further
growth in this field of research in both Europe and Japan, as FM
stated in the final comment, ‘Rome was not build in a day’.
Conclusion/perspective for the future
Through this first-ever collaborative workshop on PRO/QOL
research, both the EORTC QLG and JCOG have shared their
knowledge, experiences and current issues on PRO research and
learned from each other. For instance, as HF mentioned in his
presentation, it is still controversial how we should integrate
change of QOL score with the clinically significant meaning. Some
researchers have investigated minimal clinically important difference
(MCID) or minimally important difference (MID) in QOL scores to
establish a benchmark for assessing the efficacy of new intervention
in clinical trials (35). The EORTC QLG has also been engaged
in a project to establish MID for all QLQ-C30 scales according to
cancer sites, using individual patient data from archive EORTC trials
(36–38). The JCOG investigators will deepen understanding
of the impact of MCID or MID through this international
collaboration with the EORTC. They have decided to cooperate
more closely and work jointly to facilitate PRO research in both
groups.
EORTC QLG will actively support future PRO assessments in
the JCOG trials; the specialists of PRO/HRQL researches in EORTC
QLG will be available for consultation on trial design, selection of
proper modules for the trial, data management, statistical analyses
and collaboration projects between the EORTC and JCOG. The
EORTC QLG would let some Japanese investigators participate in
the SISAQOL consortium that has been conducted mainly by the
western countries.
The JCOG will also take a new step for PRO/QOL research in
Japan. They have decided to establish a QOL ad hoc committee; thus,
they will develop a task force for amending the current QOL research
policy to establish a proper platform and infrastructure for PRO
assessment and encourage the JCOG investigators to include QOL
objectives and endpoints in their trials. The committee members plan
to amend the JCOGQOL policy to update it with the current demand
and global trend on QOL researches.
The collaboration between the EORTC QLG and JCOG has
just started. Although some Japanese investigators have already
worked together with the EORTC QLG for module developments
(e.g. EORTC QLQ HN-43, EORTC QLQ THY-34) (23–26), this
organized alliance will facilitate more efficient QOL research and
patient- centered cancer treatment across Europe and Asia.
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Mini-abstract
The JCOG-EORTCQOL/PROworkshopwas held on Saturday, 1 Septem-
ber 2018 in Tokyo and aimed to share the current status of QOL research
and facilitate cooperative ties between the JCOG and EORTC.
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